Gain Therapeutics
GANX
12 hedge funds and large institutions have $15M invested in Gain Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
8.88% more ownership
Funds ownership: 0% → 8.88% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Greenlight Capital
New York
|
+$7.17M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$2.95M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$864K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$763K |
| 5 |
Jane Street
New York
|
+$299K |
Top Sellers
GANX Hedge Fund Activity: Q1 2021 in Review
12 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2021, worth a combined $15M.
Buyers outnumbered sellers: 12 funds opened new GANX positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Greenlight Capital, opening a new position worth an estimated $7.17M.
- 12 institutional investors held Gain Therapeutics (GANX) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $15M of Gain Therapeutics stock for Q1 2021.
- 12 funds opened new Gain Therapeutics positions in Q1 2021 and 0 closed out, a net change of +12 holders.
- The largest Gain Therapeutics buyer in Q1 2021 was Greenlight Capital, an estimated $7.17M added.
Based on aggregated 13F filings for Q1 2021.